804 related articles for article (PubMed ID: 1525588)
1. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
[TBL] [Abstract][Full Text] [Related]
2. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
3. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.
Tallstedt L; Lundell G; Tørring O; Wallin G; Ljunggren JG; Blomgren H; Taube A
N Engl J Med; 1992 Jun; 326(26):1733-8. PubMed ID: 1489388
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine therapy versus antithyroid medications for Graves' disease.
Ma C; Xie J; Wang H; Li J; Chen S
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
[TBL] [Abstract][Full Text] [Related]
6. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study.
Marcocci C; Bruno-Bossio G; Manetti L; Tanda ML; Miccoli P; Iacconi P; Bartolomei MP; Nardi M; Pinchera A; Bartalena L
Clin Endocrinol (Oxf); 1999 Oct; 51(4):503-8. PubMed ID: 10583319
[TBL] [Abstract][Full Text] [Related]
7. Relationship between management of hyperthyroidism and course of the ophthalmopathy.
Bartalena L; Tanda ML; Piantanida E; Lai A; Pinchera A
J Endocrinol Invest; 2004 Mar; 27(3):288-94. PubMed ID: 15165006
[TBL] [Abstract][Full Text] [Related]
8. Management of Graves' ophthalmopathy: reality and perspectives.
Bartalena L; Pinchera A; Marcocci C
Endocr Rev; 2000 Apr; 21(2):168-99. PubMed ID: 10782363
[TBL] [Abstract][Full Text] [Related]
9. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism.
Bartalena L; Marcocci C; Bogazzi F; Panicucci M; Lepri A; Pinchera A
N Engl J Med; 1989 Nov; 321(20):1349-52. PubMed ID: 2811943
[TBL] [Abstract][Full Text] [Related]
10. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group.
Törring O; Tallstedt L; Wallin G; Lundell G; Ljunggren JG; Taube A; Sääf M; Hamberger B
J Clin Endocrinol Metab; 1996 Aug; 81(8):2986-93. PubMed ID: 8768863
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective.
Tallstedt L; Lundell G
Thyroid; 1997 Apr; 7(2):241-5. PubMed ID: 9133694
[TBL] [Abstract][Full Text] [Related]
12. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and prevention of Graves' ophthalmopathy.
Wiersinga WM; Bartalena L
Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767
[TBL] [Abstract][Full Text] [Related]
14. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.
Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Lepri A; Pinchera A
J Endocrinol Invest; 1991 Nov; 14(10):853-60. PubMed ID: 1802923
[TBL] [Abstract][Full Text] [Related]
15. [Radioiodine versus surgery in the treatment of Graves' hyperthyroidism].
Jukić T; Stanicić J; Petric V; Kusić Z
Lijec Vjesn; 2010; 132(11-12):355-60. PubMed ID: 21294325
[TBL] [Abstract][Full Text] [Related]
16. Chronology of Graves' ophthalmopathy in an incidence cohort.
Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA
Am J Ophthalmol; 1996 Apr; 121(4):426-34. PubMed ID: 8604736
[TBL] [Abstract][Full Text] [Related]
17. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism.
Manso PG; Furlanetto RP; Wolosker AM; Paiva ER; de Abreu MT; Maciel RM
Thyroid; 1998 Jan; 8(1):49-52. PubMed ID: 9492153
[TBL] [Abstract][Full Text] [Related]
18. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy of Four Treatments in Patients with Graves' Disease: a Network Meta-analysis.
Ren Z; Qin L; Wang JQ; Li Y; Li J; Zhang RG
Exp Clin Endocrinol Diabetes; 2015 May; 123(5):317-22. PubMed ID: 25988881
[TBL] [Abstract][Full Text] [Related]
20. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
